These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12099151)

  • 21. Enalapril in Raynaud's phenomenon.
    Janini SD; Scott DG; Coppock JS; Bacon PA; Kendall MJ
    J Clin Pharm Ther; 1988 Apr; 13(2):145-50. PubMed ID: 2839529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Laser Doppler-recorded venoarteriolar reflex in Raynaud's phenomenon.
    Stoyneva Z
    Auton Neurosci; 2004 Nov; 116(1-2):62-8. PubMed ID: 15556839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reproducibility of cold provocation in patients with Raynaud's phenomenon.
    Wigley FM; Malamet R; Wise RA
    J Rheumatol; 1987 Aug; 14(4):751-5. PubMed ID: 3668980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Nicardipine in the treatment of Raynaud's phenomenon].
    Kahan A; Amor B; Menkès CJ
    Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):487-90. PubMed ID: 3303287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triiodothyronine treatment for Raynaud's phenomenon: a controlled trial.
    Dessein PH; Morrison RC; Lamparelli RD; van der Merwe CA
    J Rheumatol; 1990 Aug; 17(8):1025-8. PubMed ID: 2213778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of pinacidil in patients with primary Raynaud's phenomenon.
    Dompeling EC; Smit AJ
    Vasa Suppl; 1992; 34():34-7. PubMed ID: 1529416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.
    Coleiro B; Marshall SE; Denton CP; Howell K; Blann A; Welsh KI; Black CM
    Rheumatology (Oxford); 2001 Sep; 40(9):1038-43. PubMed ID: 11561116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis.
    Herrick AL; van den Hoogen F; Gabrielli A; Tamimi N; Reid C; O'Connell D; Vázquez-Abad MD; Denton CP
    Arthritis Rheum; 2011 Mar; 63(3):775-82. PubMed ID: 21360507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Validity of plethysmography and the digital temperature recovery test in the diagnosis of primary and occupational Raynaud's phenomenon].
    Laroche GP; Thériault G
    Clin Invest Med; 1987 Mar; 10(2):96-102. PubMed ID: 3581549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease.
    Sunderland GT; Belch JJ; Sturrock RD; Forbes CD; McKay AJ
    Clin Rheumatol; 1988 Mar; 7(1):46-9. PubMed ID: 3044673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes.
    Vayssairat M
    J Rheumatol; 1996 Nov; 23(11):1917-20. PubMed ID: 8923366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of severe Raynaud's syndrome by injection of autologous blood pretreated by heating, ozonation and exposure to ultraviolet light (H-O-U) therapy.
    Cooke ED; Pockley AG; Tucker AT; Kirby JD; Bolton AE
    Int Angiol; 1997 Dec; 16(4):250-4. PubMed ID: 9543222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon.
    Corbin DO; Wood DA; Macintyre CC; Housley E
    Eur Heart J; 1986 Feb; 7(2):165-70. PubMed ID: 3516704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nifedipine in Raynaud's phenomenon: relationship between immediate, short term and longterm effects.
    Kallenberg CG; Wouda AA; Kuitert JJ; Tijssen J; Wesseling H
    J Rheumatol; 1987 Apr; 14(2):284-90. PubMed ID: 3598997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Raynaud's phenomenon.
    García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Pardo-Santos R; Levy R; Maldonado CG; Chávez GP; Cervera R
    Autoimmun Rev; 2008 Oct; 8(1):62-8. PubMed ID: 18692160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Raynaud's phenomena: diagnostic and treatment study].
    Priollet P
    Rev Prat; 1998 Oct; 48(15):1659-64. PubMed ID: 9814067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of myofascial release techniques in the treatment of primary Raynaud's phenomenon.
    Walton A
    J Bodyw Mov Ther; 2008 Jul; 12(3):274-80. PubMed ID: 19083682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon: a double blind placebo controlled trial.
    Wise RA; Malamet R; Wigley FM
    J Rheumatol; 1987 Apr; 14(2):278-83. PubMed ID: 3298649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial.
    Muir AH; Robb R; McLaren M; Daly F; Belch JJ
    Vasc Med; 2002; 7(4):265-7. PubMed ID: 12710841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.